Immune checkpoint inhibitors (ICIs), which reinvigorate exhausted T cells by blocking inhibitory pathways such as PD-1/PD-L1 and CTLA-4, have achieved remarkable success in treating certain cancers [22–26]. Here, CTLA4 is linked to cancer.